This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
by Ahan Chakraborty
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
SNYNegative Net Change RHHBYNegative Net Change RLAYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
by Zacks Equity Research
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
REGNNegative Net Change VRTXNegative Net Change MRNANegative Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
ALKSNegative Net Change AMRNPositive Net Change EXASNegative Net Change AKRONegative Net Change
biotechs
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
NVSNegative Net Change INCYNegative Net Change EXASNegative Net Change AKRONegative Net Change
biotechs
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
RDYNegative Net Change MRKNegative Net Change AMGNNegative Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
by Zacks Equity Research
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
AGENNegative Net Change AMRNPositive Net Change VKTXNegative Net Change AKRONegative Net Change
biotechs earnings medical
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change LLYNegative Net Change
biotechs earnings medical pharmaceuticals
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
by Ekta Bagri
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
BMYNegative Net Change JNJNegative Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
by Zacks Equity Research
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
ALKSNegative Net Change INCYNegative Net Change EXELPositive Net Change AKRONegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
by Ahan Chakraborty
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical oncology-screening pharmaceuticals
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
by Sundeep Ganoria
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs medical pharmaceuticals
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
by Zacks Equity Research
AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.
AZNNegative Net Change NVSNegative Net Change JNJNegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
by Zacks Equity Research
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
ALKSNegative Net Change JAZZNegative Net Change AXSMNegative Net Change ARVNNegative Net Change
biotechs
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
by Zacks Equity Research
Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.
RHHBYNegative Net Change BAYRYNegative Net Change SRPTNegative Net Change VRNAPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
by Sundeep Ganoria
ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.
BIIBNegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
by Zacks Equity Research
Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.
RHHBYNegative Net Change BAYRYNegative Net Change SRPTNegative Net Change VRNAPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
by Zacks Equity Research
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
JNJNegative Net Change BAYRYNegative Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
by Zacks Equity Research
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
GSKNegative Net Change EXASNegative Net Change VKTXNegative Net Change AKRONegative Net Change
biotechs earnings medical
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
by Zacks Equity Research
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
RCKTNegative Net Change ARVNNegative Net Change AKRONegative Net Change KROSNegative Net Change
biotechs
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
by Zacks Equity Research
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
GSKNegative Net Change ARVNNegative Net Change AKRONegative Net Change KROSNegative Net Change
biotechs
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
by Zacks Equity Research
KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.
SNYNegative Net Change GILDNegative Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
by Zacks Equity Research
Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
by Ahan Chakraborty
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Do Options Traders Know Something About Certara Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to CERT stock based on the movements in the options market lately.
CERTPositive Net Change
biotechnology biotechs medical